The University of Nebraska’s Fred & Pamela Buffett Cancer Center has pioneered the first treatment of a multiple sclerosis (MS) patient using an allogeneic chimeric antigen receptor (CAR) T-cell therapy, azercabtagene zapreleucel (azer-cel). This off-the-shelf CD19-directed CAR T therapy is designed to target overactive immune cells responsible for MS pathology within the central nervous system. The phase I trial, sponsored by TG Therapeutics and led by Professor Rana Zabad and Dr. Matthew Lunning, addresses a significant unmet need in progressive MS forms, which current disease-modifying therapies inadequately treat. Early patient outcomes report meaningful improvements in gait and functionality, heralding a potential paradigm shift in neuroimmunology treatment strategies.